J N Kochenderfer

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint A comparison and critical analysis of preclinical anticancer vaccination strategies
    J N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Exp Biol Med (Maywood) 232:1130-41. 2007
  2. doi request reprint Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 10:267-76. 2013
  3. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
  4. pmc Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:3875-86. 2010
  5. pmc Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 32:689-702. 2009
  6. pmc Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive CRC 3 3288 Bethesda, MD 20892, USA
    Clin Immunol 124:119-30. 2007
  7. pmc Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:450-60. 2007
  8. ncbi request reprint Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:8860-73. 2006
  9. pmc Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    James N Kochenderfer
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 116:4099-102. 2010
  10. pmc Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells
    Steven A Feldman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 22:107-15. 2011

Detail Information

Publications12

  1. ncbi request reprint A comparison and critical analysis of preclinical anticancer vaccination strategies
    J N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Exp Biol Med (Maywood) 232:1130-41. 2007
    ..Identification of vaccine characteristics that are associated with antitumor efficacy may aid in the development of more effective anticancer vaccination strategies...
  2. doi request reprint Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Rev Clin Oncol 10:267-76. 2013
    ..Although anti-CD19 CAR T cells are at an early stage of development, the potent antigen-specific activity observed in patients suggests that infusions of anti-CD19 CAR T cells might become a standard therapy for some B-cell malignancies...
  3. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
    ....
  4. pmc Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:3875-86. 2010
    ..Our results demonstrated impressive antilymphoma activity and profound destruction of normal B cells caused by anti-CD19-CAR-transduced T cells in a clinically relevant murine model...
  5. pmc Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 32:689-702. 2009
    ....
  6. pmc Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health 10 Center Drive CRC 3 3288 Bethesda, MD 20892, USA
    Clin Immunol 124:119-30. 2007
    ..These findings suggest strategies to increase the size of CD8(+) T cell responses generated by CpG-containing peptide vaccines that could be tested in future clinical trials...
  7. pmc Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 110:450-60. 2007
    ..This is the first report to demonstrate that CD8(+) T-cell responses capable of executing antitumor immunity can be elicited by CpG-containing vaccines during HPE...
  8. ncbi request reprint Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:8860-73. 2006
    ..This is the first report of synergism between CpG ODN and IL-2. This synergism caused a striking increase in vaccine-elicited CD8+ T cells and led to epitope-specific antitumor immunity...
  9. pmc Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    James N Kochenderfer
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 116:4099-102. 2010
    ..Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326...
  10. pmc Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells
    Steven A Feldman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 22:107-15. 2011
    ..To date, this platform has generated five clinical-grade gammaretroviral vector products, four of which are now being used in adoptive cell therapy clinical trials for the treatment of a variety of solid cancers...
  11. doi request reprint A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 183:5563-74. 2009
    ..More importantly, PBLs expressing this new version of the 4D5 CAR could not only efficiently lyse the autologous fresh tumor digests, but they could strongly suppress tumor growth in a xenogenic mouse model...
  12. ncbi request reprint Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
    James N Kochenderfer
    Section of Transplantation Immunology, Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 100:3639-45. 2002
    ..Our results demonstrate that predominant clonal T cells that appear to be antigen-driven persist in patients with MDS unresponsive to immunosuppression, but predominant clones regress in responders to immunosuppression...